X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (83) 83
index medicus (54) 54
female (53) 53
male (53) 53
middle aged (44) 44
endocrinology & metabolism (35) 35
aged (25) 25
diabetes (25) 25
type 2 diabetes (25) 25
diabetes mellitus, type 2 - drug therapy (24) 24
adult (23) 23
diabetes mellitus (22) 22
hypoglycemic agents - therapeutic use (22) 22
insulin (18) 18
risk factors (17) 17
glucose (15) 15
diabetes mellitus, type 2 - blood (14) 14
analysis (13) 13
atherosclerosis (13) 13
diabetes mellitus, type 2 - metabolism (13) 13
hematology (13) 13
insulin resistance (13) 13
blood glucose - metabolism (12) 12
cardiac & cardiovascular systems (12) 12
liraglutide (12) 12
cells, cultured (11) 11
peripheral vascular disease (11) 11
treatment outcome (11) 11
animals (10) 10
cardiovascular disease (10) 10
cardiovascular diseases - prevention & control (10) 10
diabetes mellitus, type 2 - complications (10) 10
glucagon (9) 9
insulin - pharmacology (9) 9
meta-analysis (9) 9
metaanalysis (9) 9
metformin (9) 9
obesity (9) 9
oxidative stress (9) 9
research (9) 9
cardiovascular (8) 8
cardiovascular diseases (8) 8
endothelium (8) 8
glucose - metabolism (8) 8
insulin - blood (8) 8
risk (8) 8
blood glucose - analysis (7) 7
disease (7) 7
expression (7) 7
glycated hemoglobin a - metabolism (7) 7
inflammation (7) 7
mellitus (7) 7
metabolism (7) 7
resistance (7) 7
time factors (7) 7
aged, 80 and over (6) 6
association (6) 6
cardiovascular diseases - etiology (6) 6
care and treatment (6) 6
case-control studies (6) 6
clinical trials (6) 6
diabetics (6) 6
endothelial dysfunction (6) 6
glucagon-like peptide-1 (6) 6
gluconeogenesis (6) 6
glucose clamp technique (6) 6
glycemic control (6) 6
hypoglycemic agents - adverse effects (6) 6
hypoglycemic agents - pharmacology (6) 6
insulin resistance - genetics (6) 6
insulin-resistance (6) 6
italy (6) 6
metformin - therapeutic use (6) 6
nitric oxide synthase - metabolism (6) 6
nutrition & dietetics (6) 6
phosphorylation (6) 6
physiological aspects (6) 6
physiology (6) 6
prognosis (6) 6
prospective studies (6) 6
rna, messenger - metabolism (6) 6
blood glucose - drug effects (5) 5
cardiovascular-disease (5) 5
dextrose (5) 5
exenatide (5) 5
glucagon-like peptide 1 - analogs & derivatives (5) 5
glucose metabolism (5) 5
hypertension (5) 5
hypoglycemic agents (5) 5
insulin - therapeutic use (5) 5
medical research (5) 5
mortality (5) 5
myocardial-infarction (5) 5
nitric oxide synthase type iii - metabolism (5) 5
nitric-oxide synthase (5) 5
plasma (5) 5
proto-oncogene proteins c-akt - metabolism (5) 5
receptor (5) 5
safety (5) 5
weight loss (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Hernandez, Adrian F and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Sigmon, Kristina N and Somerville, Matthew C and Thorpe, Karl M and McMurray, John J V and Del Prato, Stefano and Del Prato, Stefano and McMurray, John J.V and D'Agostino, Ralph B and Granger, Christopher B and Hernandez, Adrian F and Janmohamed, Salim and Leiter, Lawrence A and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Lopes, Renato and Mathews, Robin and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, Lauren and Sharma, Abhinav and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Greene, Deb and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and Mathieu, Chantal and Yordanov, Victor and Hramiak, Irene and Haluzik, Martin and Galatius, Søren and Guerci, Bruno and Nauck, Michael and Migdalis, Ilias and Tan, Choon Beng Kathryn and Kocsis, Gyozo and Giaccari, Andrea and Lee, Moon Kyu and Muñoz, Ernesto German Cardona and ... and Harmony Outcomes committees and investigators and Harmony Outcomes Comm Investigator
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1834 - 1844
Journal Article
Giornale italiano di cardiologia (2006), ISSN 1827-6806, 12/2016, Volume 17, Issue 12 Suppl 2, p. 20S
Diabetes treatment should include drugs with absolutely no adverse effects toward cardiovascular risk. Indeed, it would be advisable to use drugs with... 
Hypoglycemic Agents | Cardiovascular Diseases | Glucagon-Like Peptide-1 Receptor | Humans | Risk Factors | Dipeptidyl-Peptidase IV Inhibitors | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
DIABETES CARE, ISSN 0149-5992, 11/2017, Volume 40, Issue 11, pp. 1556 - 1564
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2018, Volume 20, Issue 7, pp. 1781 - 1786
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1350 - 1360
When planning cardiovascular (CV) studies in type 2 diabetes (T2D), selection of CV biomarkers is a complex issue. Because the pathophysiology of CV disease... 
clinical trial | cardiovascular disease | type 2 diabetes | C-REACTIVE PROTEIN | BRAIN NATRIURETIC PEPTIDE | MYOCARDIAL-INFARCTION | ASYMMETRIC DIMETHYLARGININE | MICROVASCULAR OUTCOMES | CIRCULATING BIOMARKERS | ENDOTHELIAL PROGENITOR CELLS | CARDIAC TROPONIN-T | NUCLEIC-ACID OXIDATION | ENDOCRINOLOGY & METABOLISM | CORONARY-HEART-DISEASE | Oxidative Stress | Cardiovascular Diseases - prevention & control | Humans | Risk | Diabetic Cardiomyopathies - physiopathology | Diabetic Cardiomyopathies - immunology | Cardiovascular Diseases - complications | Diabetic Angiopathies - physiopathology | Diabetes Mellitus, Type 2 - immunology | Diabetes Mellitus, Type 2 - therapy | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Endothelium, Vascular - immunology | Models, Cardiovascular | Endothelium, Vascular - physiopathology | Clinical Trials as Topic | Biomarkers - blood | Evidence-Based Medicine | Cardiovascular Diseases - immunology | Diabetes Mellitus, Type 2 - blood | Diabetic Angiopathies - immunology | Diabetic Cardiomyopathies - epidemiology | Diabetic Angiopathies - epidemiology | Research Design | Type 2 diabetes | Clinical trials | Medicine, Experimental | Medical research | Hypoglycemic agents | Biological markers | Oxidative stress | Diabetes mellitus | Biomarkers | Inflammation | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases
Journal Article
Diabetes, Obesity & Metabolism, ISSN 1462-8902, 2019, Volume 21, Issue 3, pp. 499 - 508
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. Materials and... 
cardiovascular disease | cardiovascular outcomes trial | GLP‐1 receptor agonist | type 2 diabetes | oral semaglutide | GLP-1 receptor agonist | METFORMIN | ADD-ON | ONCE-WEEKLY SEMAGLUTIDE | EXENATIDE | PHASE 3A | PEPTIDE-1 RECEPTOR AGONISTS | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | THERAPIES | OUTCOMES | INCRETIN | Cardiovascular Diseases - prevention & control | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - complications | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - epidemiology | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Placebos | Female | Diabetic Angiopathies - prevention & control | Metformin - administration & dosage | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Administration, Oral | Cardiovascular System - drug effects | Glucagon-Like Peptides - adverse effects | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Myocardial infarction | Cerebral infarction | Glucagon | Diabetes mellitus | Hemoglobin | Diabetes | Safety | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Clinical Trial Design
Journal Article